-
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TWEAK with potent antitumor activity. -
UC2288 is a cell-permeable p21 attenuator. UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels. -
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
Categories
Diseases
Others
Archives
- January 2023 (1)
- August 2020 (1)
- August 2019 (1)
